$4.24
0.24%
Downside
Day's Volatility :9.62%
Upside
9.4%
20.75%
Downside
52 Weeks Volatility :88.1%
Upside
84.99%
Period | Acelyrin, Inc. | Index (Russel 2000) |
---|---|---|
3 Months | -4.93% | 0.0% |
6 Months | -49.58% | 0.0% |
1 Year | -84.3% | 0.0% |
3 Years | -81.96% | -22.3% |
Market Capitalization | 456.6M |
Book Value | $5.71 |
Earnings Per Share (EPS) | -1.94 |
Wall Street Target Price | 10.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -35.63% |
Return On Equity TTM | -43.79% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -423.6M |
Diluted Eps TTM | -1.94 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.95 |
EPS Estimate Next Year | -2.1 |
EPS Estimate Current Quarter | -0.75 |
EPS Estimate Next Quarter | -0.8 |
What analysts predicted
Upside of 147.64%
Sell
Neutral
Buy
Acelyrin, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Acelyrin, Inc. | -14.17% | -49.58% | -84.3% | -81.96% | -81.96% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Acelyrin, Inc. | NA | NA | NA | -2.95 | -0.44 | -0.36 | NA | 5.71 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Acelyrin, Inc. | Buy | $456.6M | -81.96% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Acelyrin, Inc.
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 121.4%
Organization | Acelyrin, Inc. |
Employees | 93 |
CEO | Ms. Melanie Gloria B.S.N. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$4.24
-7.22%
Keyarch Acquisition Corp
$4.24
-7.22%
Connexa Sports Technologies Inc
$4.24
-7.22%
Us Value Etf
$4.24
-7.22%
First Wave Biopharma Inc
$4.24
-7.22%
Global X Msci Next Emerging
$4.24
-7.22%
Fat Projects Acquisition Corp
$4.24
-7.22%
Capital Link Global Fintech
$4.24
-7.22%
Applied Uv Inc
$4.24
-7.22%